y 590 has been researched along with imazodan in 3 studies
| Studies (y 590) | Trials (y 590) | Recent Studies (post-2010) (y 590) | Studies (imazodan) | Trials (imazodan) | Recent Studies (post-2010) (imazodan) |
|---|---|---|---|---|---|
| 5 | 0 | 0 | 60 | 2 | 12 |
| Protein | Taxonomy | y 590 (IC50) | imazodan (IC50) |
|---|---|---|---|
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | 6 | |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A | Homo sapiens (human) | 3.4 | |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B | Homo sapiens (human) | 3.4 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Homo sapiens (human) | 6 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Homo sapiens (human) | 6 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | 6 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | 6.4778 | |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C | Homo sapiens (human) | 3.4 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | 6.4778 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bristol, JA; Humblet, CC; McPhail, AT; Moos, WH; Rithner, C; Sircar, I; Weishaar, RE | 1 |
| Bristol, JA; Cain, MH; Weishaar, RE | 1 |
| Beedle, EE; Hayes, JS; Kauffman, RF; Krushinski, JH; Pollock, GD; Robertson, DW; Wilson, H; Wyss, V | 1 |
1 review(s) available for y 590 and imazodan
| Article | Year |
|---|---|
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Blood Platelets; Calmodulin; Cardiotonic Agents; Guinea Pigs; Humans; Hypersensitivity; In Vitro Techniques; Lung Diseases; Myocardium; Platelet Aggregation; Substrate Specificity | 1985 |
2 other study(ies) available for y 590 and imazodan
| Article | Year |
|---|---|
Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cardiotonic Agents; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Myocardial Contraction; Spectrophotometry, Infrared; X-Ray Diffraction | 1987 |
Dihydropyridazinone cardiotonics: the discovery and inotropic activity of 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H -indol-2- one.
Topics: Administration, Oral; Animals; Cardiotonic Agents; Cats; Dogs; Female; In Vitro Techniques; Indoles; Male; Myocardial Contraction; Oxindoles; Platelet Aggregation; Pyridazines; Structure-Activity Relationship | 1986 |